Boston Biotech Enterprise vs Raleigh Research Triangle
Empirical head-to-head comparison across base wage, sign-on bonuses, performance incentives, 401(k) employer match vesting, 4-year equity grants with 1-year cliff, health premiums, statutory tax brackets, and HUD Fair Market Rent.
Equity / RSU Market Trajectory Stress-Test
Simulate how unvested RSUs perform under fluctuating market conditions over the 4-year horizon.
Offer A
Offer B
Itemized Compensation & Cost Arbitrage Audit
Line-by-line financial audit: Gross cash, equity realization, statutory payroll withholdings, and real cost-of-living adjustments.
| Compensation / Cost Component | Biotech company | Pharmaceutical company | Delta ($) | Advantage Winner |
|---|---|---|---|---|
Base Annual SalaryContracted baseline annual cash compensation | $170,000 | $145,000 | -$25,000 | Offer A (+15%) |
Year 1 Signing BonusUpfront one-time starting incentive | $25,000 | $15,000 | -$10,000 | Offer A (+40%) |
Target Cash BonusAnnualized performance incentive | $34,000 | $21,750 | -$12,250 | Offer A (+36%) |
4-Year Total RSU GrantFull 4-year equity or unit allocation | $120,000 | $60,000 | -$60,000 | Offer A (+50%) |
Year 1 Equity VestedFirst year stock realization (at current multiplier) | $30,000 | $15,000 | -$15,000 | Offer A (+50%) |
Annual 401(k) Employer MatchPre-tax employer retirement contribution | $5,100 | $8,700 | +$3,600 | Offer B (+71%) |
Year 1 Total Gross CompSum of base, signing, bonus, and year-1 RSUs | $259,000 | $196,750 | -$62,250 | Offer A (+24%) |
Annualized 4-Yr Gross CompSustainable average annual gross without front-loaded signing | $240,250 | $185,500 | -$54,750 | Offer A (+23%) |
Total Statutory TaxesFederal, FICA, State, and City income tax burden | $82,640 | $57,587 | -$25,052 | Offer B (+30%) |
Net Annual Take-HomeRealized gross minus all statutory tax deductions | $176,361 | $139,163 | -$37,198 | Offer A (+21%) |
Annual HUD 1BR RentLocal HUD Fair Market Rent for 1-bedroom shelter | $30,216 | $18,624 | -$11,592 | Offer B (+38%) |
Net Healthcare CostsEmployee health premium minus HSA employer contribution | $1,850 | $800 | -$1,050 | Offer B (+57%) |
Annual Commute ExpenseCommuting costs adjusted for remote work days | $2,560 | $480 | -$2,080 | Offer B (+81%) |
Net Discretionary Cash FlowNet take-home + retirement match - shelter - health - commute | $146,835 | $127,959 | -$18,876 | Offer A (+13%) |
Purchasing Power ScoreDiscretionary cash indexed to local Cost of Living | $90,265 | $93,921 | +$3,656 | Offer B (+4%) |
4-Year Realized Compensation & Cliff Horizon
Chronological earning progression factoring in 1-year equity cliff, upfront sign-on payout, and sustained base + performance bonus.
Dual Offer Evaluation & Compensation FAQs
Side-by-side total compensation evaluation for Boston Biotech Enterprise vs Raleigh Research Triangle. Model base pay, signing bonuses, 4-year RSU equity. Official 2026 economic data for Boston Biotech Enterprise vs Raleigh Research Triangle compiled from Bureau of Labor Statistics OEWS surveys, HUD Fair Market Rents, and statutory tax codes.
Quick answers
Biotech company (Boston-Cambridge-Newton, MA-NH) leaves $146,835 a year after taxes, HUD one-bedroom rent, health costs and commuting, plus the 401(k) match, versus $127,959 for Pharmaceutical company (Raleigh-Cary, NC): $18,876 more. Divided by each metro's cost-of-living index, the purchasing power scores are $90,265 and $93,921.
Year 1 total compensation adds base salary, signing bonus, target cash bonus and the first year of equity vesting (the grant divided by the vesting years). For Biotech company that is $259,000; spreading the signing bonus over the vesting period gives $240,250 a year. For Pharmaceutical company: $196,750 and $185,500. Equity refreshes and raises are not modeled.